Lauxera Capital Partners

Lauxera Capital Partners is an independent, international asset management company specializing in healthcare investments. Founded in January 2020, the firm operates from offices in Paris and San Francisco, focusing on growth-stage, scientifically de-risked healthcare businesses poised to become market leaders. Their investment strategy emphasizes partnering with motivated, world-class managers to improve healthcare system efficiency, save lives, and reduce costs. The firm's sectors of interest include medical devices, digital health, technology-enabled services, life science tools, diagnostics, and healthcare IT and data. Lauxera's first fund, Lauxera Growth I, was reserved for professional investors and obtained the French government's “Tibi” label within the framework of the institutional investors’ charter for the financing of technology companies. The firm has a track record of supporting the international commercial expansion of Europe's most promising healthtech innovations, with investments in companies such as Acandis, a German neurovascular medical device company, and Veranex, a global, tech-enabled product development services provider focused on the medical technology industry. Lauxera's approach combines operational support with capital investment, assisting portfolio companies with U.S. regulations, commercial scaling, and global expansion. This strategy has proven successful, as evidenced by the acquisition of portfolio company OrganOx by Japan’s Terumo group in August 2025 for $1.5 billion. The firm's team comprises life sciences business builders and professional healthcare investors with more than 50 years of experience, enabling them to be a strong value-add partner for their investee companies. Their highly focused investment approach, intimacy with the U.S. healthcare ecosystem, and distinctive understanding of innovation trends across Europe position Lauxera as an ideal partner for scaling healthtech solutions in the U.S. market.

Lauxera Capital Partners is an independent, international asset management company specializing in healthcare investments. Founded in January 2020, the firm operates from offices in Paris and San Francisco, focusing on growth-stage, scientifically de-risked healthcare businesses poised to become market leaders. Their investment strategy emphasizes partnering with motivated, world-class managers to improve healthcare system efficiency, save lives, and reduce costs. The firm's sectors of interest include medical devices, digital health, technology-enabled services, life science tools, diagnostics, and healthcare IT and data. Lauxera's first fund, Lauxera Growth I, was reserved for professional investors and obtained the French government's “Tibi” label within the framework of the institutional investors’ charter for the financing of technology companies. The firm has a track record of supporting the international commercial expansion of Europe's most promising healthtech innovations, with investments in companies such as Acandis, a German neurovascular medical device company, and Veranex, a global, tech-enabled product development services provider focused on the medical technology industry. Lauxera's approach combines operational support with capital investment, assisting portfolio companies with U.S. regulations, commercial scaling, and global expansion. This strategy has proven successful, as evidenced by the acquisition of portfolio company OrganOx by Japan’s Terumo group in August 2025 for $1.5 billion. The firm's team comprises life sciences business builders and professional healthcare investors with more than 50 years of experience, enabling them to be a strong value-add partner for their investee companies. Their highly focused investment approach, intimacy with the U.S. healthcare ecosystem, and distinctive understanding of innovation trends across Europe position Lauxera as an ideal partner for scaling healthtech solutions in the U.S. market.